Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17156960 | 0.83 | KDM4E (0.46) | HRH3HRH1GRM5KCNH2 | |
| SCHEMBL17156969 | 0.83 | ALDH1A1 (0.48) | HRH3 | |
| SCHEMBL17156947 | 0.82 | HRH3 (0.48) | HRH3HRH1GRM5KCNH2 | |
| SCHEMBL15736892 | 0.82 | HRH3 (0.37) | HRH3HRH1GRM5KCNH2 | |
| SCHEMBL17156965 | 0.78 | MEN1 (0.47) | HRH3HRH1GRM5KCNH2 | |
| Cadaverine Tartrate SCHEMBL15738417 | 0.78 | ALDH1A1 (0.43) | HRH3GRM5 | |
| SCHEMBL17156963 | 0.78 | GRM5 (0.48) | HRH3GRM5 | |
| SCHEMBL17156958 | 0.78 | GRM5 (0.51) | HRH3GRM5 | |
| Cadaverine Tartrate SCHEMBL173338 | 0.78 | HRH3 (0.47) | HRH3HRH1GRM5KCNH2 | |
| SCHEMBL17156955 | 0.77 | GRM5 (0.50) | HRH3GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611444-B1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2015-10-14 | — | — | EP | claimed |
| US-8912179-B2 | Heterocyclyl compounds as histamine H3 receptor ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-12-16 | — | — | US | claimed |
| US-20140148440-A1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-05-29 | — | — | US | claimed |
| EP-2611444-A1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | Suven Life Sciences Limited (IN) | 2013-07-10 | — | — | EP | claimed |
| WO-2012029070-A1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | claimed |
| EP-2611444-B1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2015-10-14 | — | — | EP | disclosed |
| US-8912179-B2 | Heterocyclyl compounds as histamine H3 receptor ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-12-16 | — | — | US | disclosed |
| US-20140148440-A1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148440-A1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | HRH3, HRH4, HRH1 | HRH3 1/4885HRH1 3/4885GRM5 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.